On June 19, 2024, Wuxi Bio successfully held its annual shareholder meeting, and all proposed resolutions were overwhelmingly supported by shareholders. This included accepting the audited financial statements and board report for the year ending December 31, 2023, as well as re-electing Dr. Zhou Weichang and Dr. Chen Jue as non-executive directors and approving the board's determination of director remuneration, reappointment of Deloitte as auditors, and granting the board general authorization for the issuance and repurchase of company shares. The meeting also approved the fourth revised and restated outline and details of the company's articles of association. The voting results of the shareholder meeting showed that all resolutions received over 98% approval, demonstrating the high level of trust and support shareholders have in the company's management team.

On June 19, 2024, Wuxi Bio successfully held its annual shareholder meeting, and all proposed resolutions were overwhelmingly supported by shareholders. This included accepting the audited financial statements and board report for the year ending December 31, 2023, as well as re-electing Dr. Zhou Weichang and Dr. Chen Jue as non-executive directors and approving the board's determination of director remuneration, reappointment of Deloitte as auditors, and granting the board general authorization for the issuance and repurchase of company shares. The meeting also approved the fourth revised and restated outline and details of the company's articles of association. The voting results of the shareholder meeting showed that all resolutions received over 98% approval, demonstrating the high level of trust and support shareholders have in the company's management team.